<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02645890</url>
  </required_header>
  <id_info>
    <org_study_id>150BPH15022</org_study_id>
    <nct_id>NCT02645890</nct_id>
  </id_info>
  <brief_title>Study to Compare the Safety and Pharmacokinetics of CKD-397</brief_title>
  <acronym>CKD-397</acronym>
  <official_title>A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetic Profiles of CKD-397 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and pharmacokinetics profiles of CKD-397
      in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, oral single dosing, two-way crossover clinical trial to evaluate
      the safety and pharmacokinetic profiles of CKD-397 in healthy male subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>CKD-397</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tadalafil/ Tamsulosin Fixed dose combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD+TM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tadalafil/ Tamsulosin Coadministration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-397</intervention_name>
    <description>Arm A:Tamsulosin/ Tadalafil Fixed dose combination</description>
    <arm_group_label>CKD-397</arm_group_label>
    <other_name>Arm A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD+TM</intervention_name>
    <description>Arm B: Tamsulosin/ Tadalafil Coadministration</description>
    <arm_group_label>TD+TM</arm_group_label>
    <other_name>Arm B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. More than 19 years in Healthy male volunteer

          2. Body weight ≥ 55kg and in the range of calculated BMI 17.5 to 30.5kg/m2

          3. Subject who signed on an informed consent form willingly

        Exclusion Criteria:

          1. Clinically significant disease with hematological, nephrological, respiratory,
             gastrointestinal, urogenital, cardiovascular, psychiatric, neurologic system and
             allergic disease (except for non-symptom seasonal allergy)

          2. Gastrointestinal disease(esophageal achalasia, esophagus stenosis, crohn's disease) or
             gastrointestinal surgery(except for appendectomy or herniotomy)

          3. Aspartate aminotransferase, Alanine aminotransferase &gt; 2 X upper limit of normal range
             or eGFR which is calculated by MDRD(Modification of diet in renal disease) &lt;
             60mL/min/1.73m2

          4. Continuously taking excessive alcohol(&gt;210g/week) within 6 months before screening

          5. Have received any other investigational drug within 3 months prior to the first dosing

          6. Sitting systolic blood pressure ≤ 100mmHg or ≥ 150mmHg, sitting diastolic blood
             pressure ≤ 60mmHg or ≥ 100mmHg

          7. Subject with orthostatic hypotension

          8. The history of drug abuse or drug abuse showed a positive for urine drug test

          9. Subject who takes inducers or inhibitors of drug metabolizing enzyme within 30 days

         10. Cigarette ≥ 20 cigarettes a day for recent 3 months and Subject who cannot stop
             smoking during clinical trial participation

         11. Subject who takes ethical drug or herbal medicine within 2 weeks or over-the-counter
             drug or vitamins within 1 week

         12. Whole blood donation within 2 months or component blood donation within 1 month or
             blood transfusion within 1 month prior to the first dosing

         13. Subject who can increase risk due to clinical test and administration of drugs or has
             severe grade / chronic medical, mental condition or abnormal laboratory result that
             may interfere with the analysis of test results.

         14. Subject with taking any forms of organic nitrate periodically and/or intermittently.

         15. Subject with known hereditary degenerative retinal disease including retinitis
             pigmentosa.

         16. Subject with serious history of hypersensitivity to investigational product (including
             Tadalafil and Tamsulosin) and other medicine (aspirin, antibiotics and so on)

         17. Subject who lost sight of one eye by non-arteritic anterior ischemic optic neuropathy
             (NAION, non-arteritic anterior ischemic optic neuropathy).

         18. Subject with genetic problems such as galactose intolerance, fructose intolerance,
             lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase
             insufficiency

         19. Subject who planned pregnancy during clinical trial and doesn't use trustworthy
             contraception

         20. Subjects who is not able to comply with guidelines described in the protocol.

         21. An impossible one who participants in clinical trials by investigator's decision
             including laboratory test result or another reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Kyu Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>9F, DongA University Hospital Department of clinical pharmacology, #26, Daechingongwon-ro, seo-gu, busan, 49201, KOREA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dong A University Hospital</name>
      <address>
        <city>Seo-gu</city>
        <state>Busan</state>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <keyword>Healthy Male Volunteer</keyword>
  <keyword>Tamsulosin</keyword>
  <keyword>Tadalafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

